Clinical Trials Logo

Rabies Vaccine Adverse Reaction clinical trials

View clinical trials related to Rabies Vaccine Adverse Reaction.

Filter by:
  • Completed  
  • Page 1

NCT ID: NCT06078423 Completed - Clinical trials for Rabies Vaccine Adverse Reaction

A Clinical Trial of Freeze-dried Human Rabies Vaccine (MRC-5 Cells)

Start date: October 19, 2019
Phase: Phase 3
Study type: Interventional

This trial is a randomized, blind, similar vaccine controlled, single center, non-inferiority design phase III clinical trial, with a study population of 10 to 60 years old, conducted in two stages.Phase 1 and Phase 2

NCT ID: NCT03741270 Completed - Clinical trials for Rabies Vaccine Adverse Reaction

Safety of Rabivax-S for Pre-exposure Prophylaxis

Start date: October 24, 2018
Phase: Phase 4
Study type: Interventional

People who are at frequent or continuous risk of exposure to rabies virus should be vaccinated against the disease (pre-exposure prophylaxis). This includes people who work with rabies virus in research or diagnostic laboratories or vaccine production facilities, veterinarians, staff, animal-control and wildlife workers in areas where rabies is endemic. Veterinary students in clinical placements and externships are included in this category. Currently, DVM students at Ross University School of Veterinary Medicine (RUSVM) are vaccinated against rabies in their 7th semester (final pre-clinical semester). Vaccinations are done by RUSVM Health Services using Rabivax-S, produced by the Serum Institute of India (study co-sponsors). Previously-unvaccinated students receive three injections of vaccine, on day 0, 7 and 21-28. The aim of the study is to generate additional data on safety and tolerability of Rabivax-S administered as pre-exposure prophylaxis to this population.